Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

AbbVie3 enrolled

Overview

The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Progressive Supranuclear Palsy (PSP)

Interventions

ABBV-8E12DRUG

Solution for infusion

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject completed Study C2N-8E12-WW-104 (NCT02494024) * Subject was not eligible to enroll in Study M15-562 (NCT02985879) Exclusion Criteria: * Subject weighs less than 35 kg at screening * Subject has any contraindication or inability to tolerate brain MRI * Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results

Locations (2)

University of California, San /ID# 170113

La Jolla, California, United States

Texas Health Physicians Group /ID# 170112

Dallas, Texas, United States

Outcomes

Primary Outcomes

Adverse Events

Adverse events and serious adverse events will be monitored throughout the dosing period and for approximately 20 weeks after the last dose.

Time frame: From first dose of study drug to 20 weeks after last dose of study drug (up to 2 years, 5 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.